Headaches

Fawad A. Khan, Alaa E. Mohammed, Mugilan Poongkunran, Anilkumar Chimakurthy, Michael Pepper November 24, 2019

Introduction

The injection interval for onabotulinumtoxinA (BoNTA) in the management of chronic migraine (CM) is 12 weeks (78‐84 days). The aim of this study was to review patient‐reported wearing off effect (WOE) of the therapeutic benefit of BoNTA near the end of the treatment cycle.… Read More...

Jan Lewis Brandes November 23, 2019

Cephalalgia, Ahead of Print.
BackgroundFremanezumab, a fully humanized monoclonal antibody targeting calcitonin gene-related peptide, has demonstrated efficacy for the preventive treatment of migraine in adults.ObjectiveTo evaluate the effect of fremanezumab treatment on acute headache medication use and migraine-associated symptoms in patients with episodic migraine.MethodsIn the Phase 3 HALO trial, patients with episodic migraine were randomized to receive subcutaneous fremanezumab monthly (225 mg at baseline, weeks 4 and 8), fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), or placebo over a 12-week period.… Read More...

Hayden Danyluk November 23, 2019

Cephalalgia, Ahead of Print.
BackgroundMany medically-refractory trigeminal neuralgia patients are non-responders to surgical treatment. Few studies have explored how trigeminal nerve characteristics relate to surgical outcome, and none have investigated the relationship between subcortical brain structure and treatment outcomes.MethodsWe retrospectively studied trigeminal neuralgia patients undergoing surgical treatment with microvascular decompression.… Read More...

Arão Belitardo Oliveira November 23, 2019

Cephalalgia, Ahead of Print.
BackgroundDisability imposed by headache disorders constitutes an expressive economic burden, mostly from indirect costs due to absenteeism and presenteeism.ObjectiveTo estimate indirect costs from absenteeism and presenteeism due to headache disorders in Brazil.MethodsIn a secondary, descriptive analysis of two nationwide databases, we estimated indirect costs based on headache-related disability and socioeconomic data.ResultsIn the first database analyzed (n = 3838), 12.8% of the employed population with headache disorders missed at least 1 day of work in the last 3 months (mean, 95% CI = 4.2 days [3.7–4.6]).… Read More...

Todd J. Schwedt, Kathleen Digre, Stewart J. Tepper, Nicole M. Spare, Jessica Ailani, Marius Birlea, Mark Burish, Laszlo Mechtler, Christopher Gottschalk, Anna M. Quinn, Linda McGillicuddy, Lisa Bance, Gina Dumkrieger, Catherine D. Chong, David W. Dodick November 23, 2019

Background

The American Registry for Migraine Research (ARMR) is a multicenter, prospective, longitudinal patient registry, biorepository, and neuroimaging repository that collects clinical data, electronic health record (EHR) data, blood samples, and brain imaging data from individuals with migraine or other headache types.… Read More...

Jaclyn R. Duvall, Ivan Garza, Narayan R. Kissoon, Carrie E. Robertson November 22, 2019

Background/Objective

The great auricular nerve (GAN) arises from C2‐C3 and provides innervation over the skin in the pre‐auricular region, jaw angle, posteroinferior pinna, and mastoid. Although damage to the GAN has been reported following trauma or procedures nearby this nerve course, neuralgia of this nerve is uncommon with knowledge based on a handful of case reports in literature.… Read More...

Ettore Marconi November 20, 2019

Cephalalgia, Ahead of Print.
BackgroundThe proper identification of chronic migraine is one of the mainstays for general practitioners. This study therefore aims to assess the epidemiology and determinants of chronic migraine in primary care in Italy by testing five operational case definition algorithms.MethodsFive case definition algorithms defining chronic migraine were developed to estimate the prevalence and incidence rate of chronic migraine in the Health Search database.… Read More...

Andoird App
Loading...